2021
A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage
Martini RP, Siler D, Cetas J, Alkayed NJ, Allen E, Treggiari MM. A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care 2021, 36: 905-915. PMID: 34873674, DOI: 10.1007/s12028-021-01398-8.Peer-Reviewed Original ResearchMeSH KeywordsBrain IschemiaCerebral InfarctionCyclohexylaminesDouble-Blind MethodEnzyme InhibitorsEpoxide HydrolasesHumansSubarachnoid HemorrhageTriazinesConceptsSoluble epoxide hydrolaseAneurysmal subarachnoid hemorrhageSubarachnoid hemorrhageDHET ratiosEnd pointDay 7Day 10Primary study end pointSoluble epoxide hydrolase inhibitionCSF inflammatory cytokinesEET/DHET ratiosIncidence of DCIPrevention of DCITertiary end pointSecondary end pointsStudy end pointCerebral blood flowLength of stayEndothelial injury biomarkersEpoxide hydrolase inhibitionNeurovascular inflammationResultsTen patientsStudy drugAdverse eventsCytokine levels
2020
Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery
Togioka BM, Yanez D, Aziz MF, Higgins JR, Tekkali P, Treggiari MM. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. British Journal Of Anaesthesia 2020, 124: 553-561. PMID: 32139135, DOI: 10.1016/j.bja.2020.01.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCholinesterase InhibitorsDelayed Emergence from AnesthesiaDouble-Blind MethodFemaleHumansIntraoperative PeriodLung DiseasesMaleNeostigmineNeuromuscular BlockadeNeuromuscular JunctionNeuromuscular Nondepolarizing AgentsPatient ReadmissionPostoperative ComplicationsRocuroniumSugammadexConceptsPostoperative pulmonary complicationsResidual neuromuscular blockPulmonary complicationsDay hospital readmissionNeuromuscular blockPrimary endpointHospital readmissionDay hospital readmission rateOlder adultsHospital readmission ratesPhase 1 recoveryRocuronium reversalNeostigmine groupSecondary endpointsSugammadex groupReadmission ratesResidual paralysisSurgical closureSugammadexComplicationsNeostigmineLarger studySurgeryIncidenceEndpoint
2015
Dexmedetomidine Does Not Affect Evoked Potentials During Spine Surgery
Rozet I, Metzner J, Brown M, Treggiari MM, Slimp JC, Kinney G, Sharma D, Lee LA, Vavilala MS. Dexmedetomidine Does Not Affect Evoked Potentials During Spine Surgery. Anesthesia & Analgesia 2015, 121: 492-501. PMID: 26097987, DOI: 10.1213/ane.0000000000000840.Peer-Reviewed Original ResearchMeSH KeywordsAnesthesia, IntravenousAnesthetics, IntravenousDexmedetomidineDouble-Blind MethodEvoked PotentialsEvoked Potentials, MotorEvoked Potentials, SomatosensoryEvoked Potentials, VisualFemaleHumansHypnotics and SedativesIntraoperative Neurophysiological MonitoringMaleMiddle AgedOrthopedic ProceduresPiperidinesPropofolReaction TimeRemifentanilSpineTime FactorsConceptsEffect of dexmedetomidineVisual EPsSpine surgeryEnd pointElective spine surgeryPlacebo-controlled trialPrimary end pointSecondary end pointsLatency N1Motor EPsPlacebo groupStudy drugAdult patientsNormal salineLatency P1DexmedetomidineSomatosensory EPsIRB approvalRelevant dosesEP recordingInformed consentPatientsSurgeryEvoked PotentialsAnesthesia
2009
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, Group E. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials 2009, 30: 256-268. PMID: 19470318, PMCID: PMC2783320, DOI: 10.1016/j.cct.2009.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinCohort StudiesCystic FibrosisDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInfantLongitudinal StudiesMalePseudomonas aeruginosaPseudomonas InfectionsRisk FactorsTobramycinTreatment OutcomeConceptsEarly Pa infectionYoung CF patientsRespiratory culturesRisk factorsCystic fibrosisCohort studyPA infectionClinical trialsObservational studyCF patientsEarly CF lung diseaseProgressive obstructive pulmonary diseaseProportion of patientsClinical efficacy dataObstructive pulmonary diseasePositive respiratory culturesPatients ages 1Longitudinal cohort studyCF lung diseaseChronic endobronchial infectionInfection control programPa acquisitionPA-negative patientsOral ciprofloxacinOral placebo